NO992187L - Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav - Google Patents

Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav

Info

Publication number
NO992187L
NO992187L NO992187A NO992187A NO992187L NO 992187 L NO992187 L NO 992187L NO 992187 A NO992187 A NO 992187A NO 992187 A NO992187 A NO 992187A NO 992187 L NO992187 L NO 992187L
Authority
NO
Norway
Prior art keywords
enzyme
tnf
methods
trre
compositions
Prior art date
Application number
NO992187A
Other languages
English (en)
Norwegian (no)
Other versions
NO992187D0 (no
Inventor
Gale A Granger
Tetsuya Gatanaga
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO992187D0 publication Critical patent/NO992187D0/no
Publication of NO992187L publication Critical patent/NO992187L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO992187A 1996-11-06 1999-05-05 Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav NO992187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3076196P 1996-11-06 1996-11-06
PCT/US1997/019930 WO1998020140A1 (en) 1996-11-06 1997-11-05 Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof

Publications (2)

Publication Number Publication Date
NO992187D0 NO992187D0 (no) 1999-05-05
NO992187L true NO992187L (no) 1999-07-01

Family

ID=21855891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992187A NO992187L (no) 1996-11-06 1999-05-05 Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav

Country Status (14)

Country Link
US (3) US6569664B1 (pt)
EP (1) EP0938548B1 (pt)
JP (1) JP2001508648A (pt)
KR (1) KR100533531B1 (pt)
AT (1) ATE403714T1 (pt)
AU (1) AU744873B2 (pt)
BR (1) BR9712900A (pt)
CA (1) CA2270898A1 (pt)
DE (1) DE69738887D1 (pt)
ID (1) ID22049A (pt)
IL (1) IL129787A0 (pt)
NO (1) NO992187L (pt)
NZ (1) NZ335864A (pt)
WO (1) WO1998020140A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
EP0938548B1 (en) * 1996-11-06 2008-08-06 The Regents of the University of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
WO1999051266A2 (en) * 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
WO2001058953A2 (en) * 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7135303B2 (en) 2000-02-28 2006-11-14 The United States Of America As Represented By The Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004096207A1 (ja) * 2003-04-30 2004-11-11 Ajinomoto Co., Inc. 体温低下抑制剤
EP1699478A2 (en) * 2003-09-23 2006-09-13 Meyer Pharmaceuticals, LLC Treating inflammation using a biological agent that causes cells to release cytokine receptors
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
WO2010080340A1 (en) 2009-01-06 2010-07-15 Siemens Healthcare Diagnostics Inc. Methods and apparatus for determining a liquid level in a container using imaging
EP3187216B1 (en) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5643740A (en) 1983-02-24 1997-07-01 Ronald J. Billing Monoclonal antibody specific for activated lymphocytes and monocytes
US5001061A (en) * 1983-06-22 1991-03-19 Lubrizol Genetics, Inc. nifD promoter of Bradyrhizobium
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
DE3585618D1 (de) 1984-10-19 1992-04-16 Chiron Corp Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns.
JPH088870B2 (ja) 1985-02-05 1996-01-31 サイナ−ゲン バイオロジカルズ，インコ−ポレ−テツド メタロプロテイナ−ゼ阻害剤の配列をもつ組換ベクタ−系及びメタロプロテイナ−ゼ阻害剤製造のための組換ｄｎａ
US4695590A (en) 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
DE69033982T2 (de) 1989-03-21 2002-10-24 Us Health Matrizenmetalloproteinase-inhibitor-peptide
US5140043A (en) 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5270326A (en) 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
JP3068879B2 (ja) 1991-03-09 2000-07-24 フマキラー株式会社 精製ダニアレルゲン
EP0534907B1 (en) 1991-09-26 1998-08-05 Nippon Zoki Pharmaceutical Co., Ltd. The use of furanone derivatives for the prevention or treatment of autoimmune diseases
DK0610286T3 (da) 1991-09-30 2000-07-17 Us Health Rekombinante immunotoxiner
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
EP0692931A4 (en) 1993-04-07 1996-03-20 Glycomed Inc SYNTHETIC INHIBITORS OF MATRIX METALLOPROTEASE AND USES
WO1995009913A1 (en) 1993-10-07 1995-04-13 Incyte Pharmaceuticals, Inc. Human monocyte/macrophage derived metalloproteinase inhibitor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
US5736356A (en) * 1994-01-28 1998-04-07 Ajinomoto Co., Inc. Transglutaminase originating from Crassostrea gigas
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
ZA955430B (en) 1994-07-07 1997-02-13 Res Dev Foundation Tumor necrosis factor receptor-ii associated protein kinase and method for their use
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6090605A (en) 1996-03-11 2000-07-18 The Board Of Trustees Of The University Of Arkansas Purified porcine kidney L-fucose kinase
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5834236A (en) 1996-06-27 1998-11-10 The Salk Institute For Biological Studies AATT repeat transcription enhancer element
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
EP0938548B1 (en) * 1996-11-06 2008-08-06 The Regents of the University of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region
US6183997B1 (en) 1997-03-21 2001-02-06 Stratagene Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same

Also Published As

Publication number Publication date
KR20000053073A (ko) 2000-08-25
JP2001508648A (ja) 2001-07-03
US6858402B2 (en) 2005-02-22
WO1998020140A1 (en) 1998-05-14
US20030170776A1 (en) 2003-09-11
KR100533531B1 (ko) 2005-12-06
ID22049A (id) 1999-08-26
BR9712900A (pt) 2000-11-28
US6569664B1 (en) 2003-05-27
EP0938548B1 (en) 2008-08-06
ATE403714T1 (de) 2008-08-15
EP0938548A1 (en) 1999-09-01
DE69738887D1 (de) 2008-09-18
IL129787A0 (en) 2000-02-29
AU5162198A (en) 1998-05-29
AU744873B2 (en) 2002-03-07
US6573062B1 (en) 2003-06-03
NZ335864A (en) 2001-09-28
CA2270898A1 (en) 1998-05-14
NO992187D0 (no) 1999-05-05

Similar Documents

Publication Publication Date Title
NO992187D0 (no) Isolert tumornekrosefaktor-reseptor utl°sende enzym, sammensetninger som omfatter enzymet og metoder for bruken derav
Sulli et al. Melatonin serum levels in rheumatoid arthritis
Roerink et al. Interleukin-1 as a mediator of fatigue in disease: a narrative review
Kane et al. The role of corticotropin‐releasing hormone in immune‐mediated cutaneous inflammatory disease
Boros et al. Fermented wheat germ extract (Avemar) in the treatment of cancer and autoimmune diseases
Page et al. Human mast cell and airway smooth muscle cell interactions: implications for asthma
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
EA200200768A1 (ru) Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
ATE281840T1 (de) Behandlung von diarrhoe
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
Miyata et al. Activation of protein kinase C βII/ε-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin
Chang et al. Ferroptosis in inflammatory arthritis: a promising future
NO982185L (no) Nye makrosykliske forbindelser som metalloproteinaseinhibitorer
Corrado et al. Bone effects of biologic drugs in rheumatoid arthritis
Okamura et al. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis
Wang et al. Alternative Expression Pattern of MALT1-A20-NF-B in Patients with Rheumatoid Arthritis
Sun et al. Eomes impedes durable response to tumor immunotherapy by inhibiting stemness, tissue residency, and promoting the dysfunctional state of intratumoral CD8+ T cells
Fernandez-Vojvodich et al. Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth
Dos Anjos et al. Modulation of immune response to induced‐arthritis by low‐level laser therapy
Ruest et al. Activation of Receptor Activator of Nuclear Factor‐κB Ligand and Matrix Metalloproteinase Production in Periodontal Fibroblasts by Endothelin Signaling
Evans et al. Natural human IL-1β exhibits regulatory actions on human bone-derived cells invitro
Diller et al. The activin-follistatin anti-inflammatory cycle is deregulated in synovial fibroblasts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application